Clinical trial · Interventional
Liposomal Irinotecan and Apatinib in ES-SCLC
Study of Liposomal Irinotecan Combined with Apatinib in the Treatment of Extensive Stage Small Cell Lung Cancer After First-line Progression
NCT06749691CI-TRIAL-00084082LIAESrecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer Extensive Stage | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liposomal Irinotecan and Apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Liposomal Irinotecan and Apatinib
- interventionNames
- Drug: Liposomal Irinotecan and Apatinib
Primary outcomes (1)
- measure
- Progression-Free-Survival rate at 6 months
- timeFrame
- From enrollment at 6 months
- description
- Progression-Free-Survival rate at 6 months from enrollment
Secondary outcomes (3)
- measure
- ORR
- timeFrame
- From enrollment to the end of treatment at 6-8 weeks
- description
- Overall Response Rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age range of 18-75 years; 2. Expected survival period ≥ 12 weeks; 3. At least one measurable lesion (according to RECIST V 1.1); 4. For patients who have failed first-line or second-line treatment. Exclusion Criteria: 1. Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib. 2. Active or uncontrolled severe infection (CTCAE 5.0 ≥ 2) and/or antibiotic treatment within 2 weeks prior to enrollment; 3. There are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction; 4. Those deemed unsuitable for inclusion by doctors;
References
Publications (0)
Data not yet available
No reference posted for this study.